Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Continued progress with lead program, CX-2051 (EpCAM PROBODY® Topo-1 ADC), in Phase 1a study in advanced colorectal cancer with initial Phase 1a clinical data to be presented in 1H 2025 - - CX-801 ...

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive officer and chairman, will ...

Collaboration revenue under the AbbVie Agreement was fully recognized as of December ... operations from our laboratory and offices in Newark, California to our South San Francisco Headquarters. Net ...

The increase in operating expenses was primarily due to a $5.0 million milestone payment to AbbVie (formerly ImmunoGen) as a result of dosing the first patient for CX-2051 in Phase 1 based upon ...

The appeals court, based in San Francisco, denied a request from the ... Senator John Thune of South Dakota, the majority leader, said Republicans planned to continue with their tactic of ...

Visitors have been able to stroll near a South San Francisco sign since 1923, when the city's Chamber of Commerce built the ...

Shvo and partner Deutsche Finance America paid $650 million for the the tower and accompanying plaza in late 2020.

Developer goes from “contrarian” to conviction for 360K sf trophy tower at 530 Sansome Street, in the North Financial ...